Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
– Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market
– Technology development focused on the PGX pilot scale units
Related news for (CRPOF)
- Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
- Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
- Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company